Efficacy of remimazolam with fentanyl vs midazolam with fentanyl for sedation in screening colonoscopy: Randomized controlled study
Endoscopy International Open · 15.08.2025 · 13 (CP)
DOI: 10.1055/a-2655-1083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy International Open, erschienen am 15.08.2025. Verfasst von Andrea C Armbrecht und 5 weiteren Autor:innen. Beteiligte Einrichtung: Herlev, Herlev Hospital, Herlev, Denmark. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Remimazolam is a new ultra-short-acting benzodiazepine with a favorable safety-profile when used for sedation in endoscopy. The aim of this project was to investigate efficacy of remimazolam with fentanyl compared with midazolam with fentanyl for sedation in colonoscopy among fecal immunochemical test (FIT)-positive screening participants. The study was a prospective, single-blinded, randomized controlled trial. FIT-positive participants undergoing colonoscopy were randomized to intravenous remimazolam + fentanyl (RF) or midazolam + fentanyl (MF). Primary outcome was total time from start of medication until discharge. Secondary outcomes included time to reach cecum, need for post-procedure recovery, patient-reported pain and satisfaction, need for additional medication, and procedure completion. A total of 205 patients were included and randomized 1:1 (RF:103, MF:102). Mean age was 62.6 years, whereas female/male ratio was 97/108. Mean time from start of medication until discharge was 29.9 minutes (RF) versus 35.0 minutes (MF) (95% confidence interval 0.77–0.94, P = 0.012). Mean time to reach the cecum was 15.4 minutes (RF) compared with 20.2 minutes (MF) (P = 0.001). Proportion of patients requiring postoperative observation was lower for RF 0.97% vs 9.8% for MF (P = 0.022). Patients receiving remimazolam reported an average lower pain score (mean 2.25 (RF) vs 3.25 (MF) P = 0.012) and higher overall satisfaction score (4.65 vs 4.33, P = 0.012). This study shows clear superiority of the combination of remimazolam with fentanyl over midazolam with fentanyl for conscious sedation in screening colonoscopy, obtaining shorter procedure time, less postoperative need for observation, lower patient pain scores, and higher patient satisfaction.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Herlev, Herlev Hospital, Herlev, Denmark.
- Antioquia, Universidad de Antioquia, Medellin, Colombia.
- Gastro Unit, Division of Endoscopy, Copenhagen University Hospital Herlev, Herlev, Denmark.
- Medicinsk afdeling, Dronning Ingridip Napparsimmavissua, Nuuk, Greenland.
- SUND, Københavns Universitet Det Sundhedsvidenskabelige Fakultet, Kobenhavn, Denmark.
- Anaesthesia, Copenhagen University Hospital Herlev, Herlev, Denmark.
Zitieren
APA
Armbrecht, A. C., Kovacevic, B., Rasmussen, M. D., Bernth, M. K., Moeller, A. M., & Vilmann, P. (2025). Efficacy of remimazolam with fentanyl vs midazolam with fentanyl for sedation in screening colonoscopy: Randomized controlled study. Endoscopy International Open, 13(CP). https://doi.org/10.1055/a-2655-1083
Vancouver
Armbrecht AC, Kovacevic B, Rasmussen MD, Bernth MK, Moeller AM, Vilmann P. Efficacy of remimazolam with fentanyl vs midazolam with fentanyl for sedation in screening colonoscopy: Randomized controlled study. Endoscopy International Open. 2025;13(CP). doi:10.1055/a-2655-1083
BibTeX
@article{Armbrecht2025,
author = {Armbrecht, Andrea C and Kovacevic, Bojan and Rasmussen, Maria Dyrehave and Bernth, Michelle Katharina and Moeller, Ann Merete and Vilmann, Peter},
title = {Efficacy of remimazolam with fentanyl vs midazolam with fentanyl for sedation in screening colonoscopy: Randomized controlled study},
journal = {Endoscopy International Open},
year = {2025},
volume = {13},
number = {CP},
doi = {10.1055/a-2655-1083}
}
EUVIMED